DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
TONAPOFYLLINE
2
Small molecule
Investigational
Unknown
Unknown
Liver Diseases; Heart Failure; Renal Insufficiency
Adenosine A1 receptor antagonist
TONAPOFYLLINE
×
Maximum Phase:
2
First Approval:
None
UNII:
83VNU4U44T
Molecule Type:
Small molecule
Molecular Formula:
C22H32N4O4
Molecular Weight:
416.52
AlogP:
3.16
PSA:
109.98
HBD:
2.0
HBA:
#RotB:
8.0
Source:
IDOXIFENE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Estrogen receptor modulator
IDOXIFENE
×
Maximum Phase:
2
First Approval:
None
UNII:
456UXE9867
Molecule Type:
Small molecule
Molecular Formula:
C28H30INO
Molecular Weight:
523.46
AlogP:
7.13
PSA:
12.47
HBD:
0.0
HBA:
#RotB:
8.0
Source:
LY2196044
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
LY2196044
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BALUGRASTIM
2
Protein
Investigational
Unknown
Unknown
Neoplasms
Granulocyte colony stimulating factor receptor agonist
BALUGRASTIM
×
Maximum Phase:
2
First Approval:
None
UNII:
T6K4P3HIU8
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CINNAMON
2
Unknown
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Obesity; Dental Caries; Diabetes Mellitus; Polycystic Ovary Syndrome
Unknown
CINNAMON
×
Maximum Phase:
2
First Approval:
None
UNII:
5S29HWU6QB
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EZALADCIGENE RESOPARVOVEC
2
Gene
Investigational
Unknown
Unknown
Parkinson Disease
Unknown
EZALADCIGENE RESOPARVOVEC
×
Maximum Phase:
2
First Approval:
None
UNII:
2WRS0PE04O
Molecule Type:
Gene
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OLESTRA
2
Unknown
Investigational
Unknown
Unknown
Obesity
Unknown
OLESTRA
×
Maximum Phase:
2
First Approval:
None
UNII:
6742Y30KGK
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MS1819-SD
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
MS1819-SD
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
81C6 131I
2
Antibody
Investigational
Unknown
Unknown
Unknown
Tenascin binding agent
81C6 131I
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DWP05195
2
Small molecule
Investigational
Unknown
Unknown
Neuralgia, Postherpetic
Vanilloid receptor antagonist
DWP05195
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DELTA 8-TETRAHYDROCANNOBINOL
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms
Unknown
DELTA 8-TETRAHYDROCANNOBINOL
×
Maximum Phase:
2
First Approval:
None
UNII:
B49D0HH807
Molecule Type:
Small molecule
Molecular Formula:
C21H30O2
Molecular Weight:
314.47
AlogP:
5.74
PSA:
29.46
HBD:
1.0
HBA:
#RotB:
4.0
Source:
KANGLAITE
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
KANGLAITE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
(-)-EPICATECHIN
2
Small molecule
Investigational
Unknown
Unknown
Hypertension, Pulmonary; Muscular Dystrophy, Duchenne
Unknown
(-)-EPICATECHIN
×
Maximum Phase:
2
First Approval:
None
UNII:
34PHS7TU43
Molecule Type:
Small molecule
Molecular Formula:
C15H14O6
Molecular Weight:
290.27
AlogP:
1.55
PSA:
110.38
HBD:
5.0
HBA:
#RotB:
1.0
Source:
SAR-279356
2
Antibody
Investigational
Unknown
Unknown
Infections
Poly-N-acetylglucosamine binding agent
SAR-279356
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PEGAMOTECAN
2
Small molecule
Investigational
Unknown
Unknown
Sarcoma
Unknown
PEGAMOTECAN
×
Maximum Phase:
2
First Approval:
None
UNII:
ZY7ZTE7LFH
Molecule Type:
Small molecule
Molecular Formula:
C52H48N6O14
Molecular Weight:
980.98
AlogP:
3.32
PSA:
251.64
HBD:
2.0
HBA:
#RotB:
15.0
Source:
TRANSCON CNP
2
Unknown
Investigational
Unknown
Unknown
Achondroplasia
Unknown
TRANSCON CNP
×
Maximum Phase:
2
First Approval:
None
UNII:
Y3BH8M899D
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NAXIFYLLINE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Adenosine A1 receptor antagonist
NAXIFYLLINE
×
Maximum Phase:
2
First Approval:
None
UNII:
B3G45WC37L
Molecule Type:
Small molecule
Molecular Formula:
C18H24N4O3
Molecular Weight:
344.42
AlogP:
1.6
PSA:
85.21
HBD:
1.0
HBA:
#RotB:
5.0
Source:
PD-L1
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
PD-L1
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SIMOLADAGENE AUTOTEMCEL
2
Gene
Investigational
Unknown
Unknown
Severe Combined Immunodeficiency
Unknown
SIMOLADAGENE AUTOTEMCEL
×
Maximum Phase:
2
First Approval:
None
UNII:
MOD3RG31RS
Molecule Type:
Gene
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CIFORADENANT
2
Small molecule
Investigational
Unknown
Unknown
Attention Deficit Disorder with Hyperactivity; Carcinoma, Non-Small-Cell Lung; Multiple Myeloma; Parkinson Disease
Adenosine A2a receptor antagonist
CIFORADENANT
×
Maximum Phase:
2
First Approval:
None
UNII:
8KFO2187CP
Molecule Type:
Small molecule
Molecular Formula:
C20H21N7O3
Molecular Weight:
407.43
AlogP:
2.12
PSA:
127.0
HBD:
1.0
HBA:
#RotB:
6.0
Source:
ANTIMONY CATION (5+)
2
Small molecule
Investigational
Unknown
Unknown
Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous
Unknown
ANTIMONY CATION (5+)
×
Maximum Phase:
2
First Approval:
None
UNII:
841L03HG64
Molecule Type:
Small molecule
Molecular Formula:
Sb+5
Molecular Weight:
121.76
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
LADIRATUZUMAB VEDOTIN
2
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Hemangiosarcoma
Tubulin inhibitor
LADIRATUZUMAB VEDOTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
VM4G5D1A60
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PEGCANTRATINIB
2
Small molecule
Investigational
Unknown
Unknown
Neuralgia; Dermatitis, Atopic; Psoriasis
Nerve growth factor receptor Trk-A inhibitor
PEGCANTRATINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
VG44NU1168
Molecule Type:
Small molecule
Molecular Formula:
C30H24N4O6
Molecular Weight:
536.54
AlogP:
4.12
PSA:
104.03
HBD:
1.0
HBA:
#RotB:
3.0
Source:
.ALPHA.-R-LIPOIC ACID CHOLINE ESTER
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
.ALPHA.-R-LIPOIC ACID CHOLINE ESTER
×
Maximum Phase:
2
First Approval:
None
UNII:
H3PX4O36U1
Molecule Type:
Small molecule
Molecular Formula:
C13H26NO2S2+
Molecular Weight:
292.49
AlogP:
2.95
PSA:
26.3
HBD:
0.0
HBA:
#RotB:
8.0
Source:
XL-820
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Gastrointestinal Stromal Tumors
Platelet-derived growth factor receptor inhibitor
XL-820
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RIMACALIB
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
Unknown
RIMACALIB
×
Maximum Phase:
2
First Approval:
None
UNII:
BZ76J3N815
Molecule Type:
Small molecule
Molecular Formula:
C22H23FN4O2
Molecular Weight:
394.45
AlogP:
4.31
PSA:
74.38
HBD:
2.0
HBA:
#RotB:
4.0
Source:
VEDROPREVIR
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C, Chronic
Hepatitis C virus serine protease, NS3/NS4A inhibitor
VEDROPREVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
KGD958X2B9
Molecule Type:
Small molecule
Molecular Formula:
C45H60ClN7O9S
Molecular Weight:
910.53
AlogP:
6.2
PSA:
193.78
HBD:
4.0
HBA:
#RotB:
16.0
Source:
VOPRATELIMAB
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Neoplasms
Inducible T-cell costimulator agonist
VOPRATELIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
QXN20J93AH
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMDOXOVIR
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
AMDOXOVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
54I81H0M9C
Molecule Type:
Small molecule
Molecular Formula:
C9H12N6O3
Molecular Weight:
252.23
AlogP:
-1.15
PSA:
134.33
HBD:
3.0
HBA:
#RotB:
2.0
Source:
OLINCIGUAT
2
Small molecule
Investigational
Unknown
Unknown
Anemia, Sickle Cell; Esophageal Achalasia
Soluble guanylate cyclase positive allosteric modulator
OLINCIGUAT
×
Maximum Phase:
2
First Approval:
None
UNII:
PD5F4ZXD21
Molecule Type:
Small molecule
Molecular Formula:
C21H16F5N7O3
Molecular Weight:
509.4
AlogP:
2.51
PSA:
144.98
HBD:
3.0
HBA:
#RotB:
8.0
Source:
ANRUKINZUMAB
2
Antibody
Investigational
Unknown
Unknown
Asthma; Colitis, Ulcerative
Interleukin-13 inhibitor
ANRUKINZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
OU46IGC49F
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ODRONEXTAMAB
2
Antibody
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Follicular
B-lymphocyte antigen CD20 binding agent
ODRONEXTAMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
8R5CM46UIO
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ZD-6126
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Renal Cell; Colorectal Neoplasms; Neoplasm Metastasis
Unknown
ZD-6126
×
Maximum Phase:
2
First Approval:
None
UNII:
GBO3S6M9W7
Molecule Type:
Small molecule
Molecular Formula:
C20H24NO8P
Molecular Weight:
437.39
AlogP:
2.97
PSA:
123.55
HBD:
3.0
HBA:
#RotB:
6.0
Source:
GOZETOTIDE ALF-18
2
Small molecule
Investigational
Unknown
Unknown
Prostatic Neoplasms
Unknown
GOZETOTIDE ALF-18
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C44H60AlFN6O17
Molecular Weight:
989.97
AlogP:
1.55
PSA:
370.07
HBD:
12.0
HBA:
#RotB:
35.0
Source:
PENTALYTE
2
Small molecule
Investigational
Unknown
Unknown
Nasopharyngeal Neoplasms
Unknown
PENTALYTE
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
H3Cl2K2MgNa3O12P2S
Molecular Weight:
531.4
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
1
2
…
160
161
162
163
164
165
166
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA